New hope for tough lung cancer: tarlatamab trial targets advanced disease

NCT ID NCT06502977

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests a drug called tarlatamab in 32 Chinese adults with advanced small cell lung cancer that has worsened after at least two prior treatments. The main goal is to see if the drug can shrink tumors. Researchers will also monitor side effects and how long any response lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tarlatamab (a drug given by IV infusion)
What this could lead to: If successful, this could provide a new treatment option for Chinese patients with advanced small cell lung cancer who have run out of standard therapies.
What could go wrong: This is an early Phase 2 study with only 32 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm neuroendocrine neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Army Special Medical Center of Peoples Liberation Army

Chongqing, Chongqing Municipality, 400042, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Fujian Cancer Hospital

Fuzhou, 350011, China
Harbin Meidical University Cancer Hospital

Harbin, Heilongjiang, 150000, China
Jiangmen Central Hospital

Jiangmen, Guangdong, 529000, China
Mengchao Hepatobiliary Hospital of Fujian Medical University

Fuzhou, Fujian, 350025, China
Sun Yat-Sen University Cancer Center

Guangzhou, Guangdong, 510060, China
Taizhou Hospital of Zhejiang Province

Linhai, Zhejiang, 317000, China
The Second Affiliated Hospital of Army Medical University, People's Liberation Army

Chongqing, Chongqing Municipality, 400037, China
The Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China
Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.